Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Cut by Eventide Asset Management LLC

Key Points

• Eventide Asset Management LLC reduced its stake in Alnylam Pharmaceuticals by 30.8%, now holding approximately $44.94 million, or about 0.13% of the company.
• Alnylam Pharmaceuticals received multiple upgrade ratings from analysts, including a price target increase to $570.00 by HC Wainwright, highlighting positive market sentiment.
• Alnylam reported earnings exceeding analysts' expectations with revenue of $773.69 million for the last quarter, marking a 17.3% increase from the previous year.

Eventide Asset Management LLC decreased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 30.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 166,450 shares of the biopharmaceutical company's stock after selling 73,968 shares during the period. Eventide Asset Management LLC owned approximately 0.13% of Alnylam Pharmaceuticals worth $44,943,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. SVB Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals in the first quarter worth about $27,000. Whipplewood Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares in the last quarter. Bessemer Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares in the last quarter. Park Square Financial Group LLC acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $28,000. Finally, Colonial Trust Co SC acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $35,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Insiders Place Their Bets

In related news, Director Dennis A. Ausiello sold 31,448 shares of the stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the transaction, the director directly owned 911 shares of the company's stock, valued at $397,724.38. This represents a 97.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $1,030,735.98. Following the completion of the transaction, the executive vice president directly owned 50,121 shares of the company's stock, valued at $22,718,345.67. This trade represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 57,594 shares of company stock worth $25,551,456. 1.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

ALNY has been the topic of several recent analyst reports. UBS Group boosted their price target on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Truist Financial began coverage on Alnylam Pharmaceuticals in a research note on Monday, July 21st. They set a "buy" rating and a $385.00 price objective on the stock. Needham & Company LLC upped their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a "buy" rating in a research note on Thursday, July 31st. Scotiabank upped their price objective on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a research note on Friday, August 1st. Finally, Wells Fargo & Company upped their price objective on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $417.38.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock traded up $3.03 on Monday, reaching $455.03. 925,938 shares of the company were exchanged, compared to its average volume of 958,623. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The company's 50-day moving average is $387.47 and its two-hundred day moving average is $310.11. The firm has a market cap of $59.65 billion, a price-to-earnings ratio of -184.22 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $469.81.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773.69 million for the quarter, compared to analysts' expectations of $633.54 million. During the same period in the prior year, the firm earned ($0.13) EPS. The business's quarterly revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.